A120 Hemodynamic Effects of the Pde Inhibitor Piroximone to Assist in Weaning From CPB

Tarr, T.J.; Frazer, R. S.; Moore, Nicholas; Desmond, Michael

doi:10.1097/00000542-199009001-00120

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choice of drug doses used in this study was based on previous studies in patients undergoing cardiac surgery. Beneficial haemodynamic effects of enoximone and piroximone have been demonstrated after recommended loading doses of 0.5 mg kg" 1 [7,9,[12][13][14] and maintenance infusions of enoximone 5 ug kg" 1 min" 1 [8] or piroximone 3-6 ug kg" 1 h" 1 [13]. It was important to have a stable baseline for comparisons because the numbers in each group were small.…”

Section: Resultsmentioning

confidence: 99%

“…Previous studies have investigated enoximone given before [2], during [3][4][5][6][7] and after [8][9][10] cardiopulmonary bypass. At present there is limited experience of piroximone in cardiac surgical patients [11][12][13]. and this is predictable from the pharmacokinetic profiling of Gonzalez and co-workers using similar dosing schedules [8].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the Haemodynamic Effects of Enoximone and Piroximone in Patients After Cardiac Surgery

Patel¹,

Caldicott²,

Skoyles³

et al. 1993

British Journal of Anaesthesia

View full text Add to dashboard Cite

We have compared the haemodynamic effects of the imidazole derivative phosphodiesterase inhibitors enoximone and piroximone in patients with low cardiac output after cardiac surgery. Ten patients (group E) received enoximone and 10 patients (group P) received piroximone, both at a loading dose of 0.5 mg kg-1 followed by an infusion of 5 micrograms kg-1 min-1. In both groups the main changes with time were increases in cardiac index (maximum 24.5% in group E, 25.8% in group P) and decreases in systemic vascular resistance (maximum 26.8% in group E and 24.8% in group P). There were moderate increases in heart rate (maximum 11.3% in group E and 13% in group P) but a greater percentage decrease in mean arterial pressure in group E (maximum 11.9% vs 7.9%) with time. One patient in group E developed hypertension during the loading dose. Two patients in group E and two in group P developed hypotension during the loading dose. One patient in group E developed ventricular extrasystoles which may have been related to the drug being studied.

show abstract